WideCells Group PLC Attendance at British Dental Conference (8733F)
May 23 2017 - 1:00AM
UK Regulatory
TIDMWDC
RNS Number : 8733F
WideCells Group PLC
23 May 2017
23 May 2017
WideCells Group ('WideCells' or 'the Company')
Attendance at British Dental Conference and Exhibition
WideCells Group PLC ('WideCells' or the 'Company'), the
healthcare services company focused on providing stem cell services
and ground breaking insurance for stem cell treatment, is pleased
to announce that Non-Executive Director Dr. Marilyn Orcharton will
be representing the Company at the upcoming British Dental
Conference and Exhibition, being held in Manchester from 25-27 May
2017. At the conference, Dr. Orcharton will be providing
information on the Company's plans to extend its stem cell storage
services to include dental pulp storage and processing
(TeethCells). The Company hopes to start offering this new service
to the market in the coming months and, having recognised
significant growth opportunities within the dental industry,
intends to appoint a Dental Key Account Manager to manage this
emerging revenue stream including potential strategic relationships
with distribution partners in Europe and the Middle-East.
Dr. Orcharton is a renowned figure in dentistry, having
co-founded Denplan Limited in 1986, which is still the UK's market
leader in dental insurance, with a multi-million-pound annual
turnover. WideCells is looking to achieve similar success in the
stem cell industry via its CellPlan division, which is rolling out
the world's first stem cell healthcare insurance plan.
The Company is also developing its WideCells division and is on
track to launch its second stem cell storage and contract research
facility, the Institute of Stem Cell Technology, located in the
University of Manchester Innovation Centre in Q2 2017 ('the ISCT').
The ISCT will initially offer umbilical cord progressing and
storage (BabyCells), like its existing facility in São Paulo,
Brazil. However, looking ahead it also plans to obtain a license
from the HTA ('Human Tissue Authority') to offer dental pulp
storage and processing later this year, which involves harvesting
stem cells from baby teeth (TeethCells), in line with its strategy
to build a diverse service offering to enable the storage of cells
for individuals anywhere along the age spectrum, allowing maximum
market penetration.
Dr. Orcharton's established network and experience within the
dental industry will be invaluable in supporting the development of
this new service offering and the British Dental Conference and
Exhibition provides an opportune format through which to connect
with industry leaders.
For further information on the conference please visit
https://bda.org/conference
**ENDS**
For further information, please visit the Company's website
www.widecellsgroup.com, follow us on Twitter @WideCells_Group or
contact:
WideCells Group CEO - João Andrade Tel: +351 919
033 171
------------------- ------------------------- --------------
Smaller Company Broker - Jeremy Woodgate Tel: +44 (0)
Capital Ltd & Rupert Williams 20 3651 2912
------------------- ------------------------- --------------
Shard Capital Broker - Damon Heath Tel: +44 (0)
Partners LLP & Erik Woolgar 207 186 9950
------------------- ------------------------- --------------
St Brides Partners PR - Elisabeth Cowell Tel: +44 (0)
Ltd & Charlotte Page 20 7236 1177
------------------- ------------------------- --------------
Notes to Editors
WideCells Group PLC is building an integrated stem cell services
company, focused on making stem cell treatments accessible and
affordable. The Directors believe that the use of cord blood stem
cells for transplant will drive one of the next important phases in
medicine and is therefore developing market leading products in
complementary, strategic areas which are designed to take advantage
of substantial market opportunities in one of the fastest growing
segments in the healthcare industry. With this in mind, it has
created three divisions:
-- CellPlan: the world's first stem cell healthcare insurance
plan with financial cover for medical treatment, travel and
accommodation expenses and concierge service to manage the
treatment process.
-- WideCells: the Institute of Stem Cell Technology has been
established and is based in the University of Manchester Innovation
Centre to focus on stem cell research and regenerative medicine.
WideCells also has international cryogenics divisions specialising
on stem cell storage.
-- WideAcademy: developing an education and training division to
promote awareness of the benefits of stem cell storage across the
global general practice community.
The Group has built an experienced senior management team that
has been integral to the development of its growth and business to
date.
Stem Cell Fast Facts:
-- Cord blood (which is taken from the umbilical cord) provides
the most effective source of stem cells for families due to it
being simple, safe and painless to collect relative to other
sources of stem cells such as bone marrow - WideCells will focus on
promoting the collection and storage of this.
-- Since 2005, there has been a 300% increase in the number of
illnesses that can be treated using stem cells.
-- 82 illnesses can currently be treated using stem cell procedures.
-- Despite initial storage often costing no more than a few
GBPthousand, actual treatment can cost in the GBPhundreds of
thousands.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCPGUPWAUPMGCP
(END) Dow Jones Newswires
May 23, 2017 02:00 ET (06:00 GMT)
Iconic Labs (LSE:ICON)
Historical Stock Chart
From Apr 2024 to May 2024
Iconic Labs (LSE:ICON)
Historical Stock Chart
From May 2023 to May 2024